Vemlidy

Vemlidy

tenofovir alafenamide

Manufacturer:

Gilead

Distributor:

A. Menarini
Concise Prescribing Info
Contents
Tenofovir alafenamide
Indications/Uses
Chronic hepatitis B in adults & adolescents (≥12 yr & at least 35 kg).
Dosage/Direction for Use
Adult & adolescent ≥12 yr & at least 35 kg 1 tab once daily.
Administration
Should be taken with food.
Contraindications
Special Precautions
Not for prevention of HBV transmission through sexual contact or blood contamination. Decompensated liver disease. Co-infection w/ HBV & hepatitis C or D. Closely monitor patients w/ cirrhosis. Monitor hepatic function at repeated intervals w/ clinical & laboratory follow up for at least 6 mth after treatment discontinuation. Do not discontinue treatment in patients w/ advanced liver disease or cirrhosis. Not recommended in patients w/ CrCl <15 mL/min not receiving dialysis. Nephrotoxicity. Concomitant use w/ anticonvulsants, antimycobacterials or St. John's Wort; strong P-gp inhibitors. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Dizziness during treatment may affect ability to drive or operate machinery. Renal impairment. Pregnancy & lactation.
Adverse Reactions
Headache. Diarrhea, vomiting, nausea, abdominal pain/distention, flatulence; fatigue; dizziness; rash, pruritus; increased ALT; arthralgia.
Drug Interactions
Decreased plasma conc w/ P-gp inducers (eg, rifampicin, rifabutin, carbamazepine, phenobarb, St. John's wort). Increased plasma conc w/ strong P-gp inhibitors (eg, itraconazole & ketoconazole).
MIMS Class
Antivirals
ATC Classification
J05AF13 - tenofovir alafenamide ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Presentation/Packing
Form
Vemlidy FC tab 25 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in